Recent trends have seen a rise in the use of monoclonal antibody therapeutics (mAbs) as the medical community strives towards a more personalized approach to treating diseases such as cancer and autoimmune disorders. Monoclonal Antibodies continue to be the top category of biologic drug on the market, accounting for over $52 billion in annual sales in the US. In 2016, five of the top ten revenue producing drugs were mAbs. This trend looks set to continue, and will demand a skilled technical workforce as new facilities are built to meet market needs.
Production of mAbs in Chinese Hamster Ovary (CHO) cells is a common practice in pharmaceutical companies. This miniBIOMAN hands-on workshop will cover the downstream processing stage of the mAb manufacturing process. Participants will follow standard operating procedures (SOPs) and production batch records to perform each stage of the process, including tangential flow filtration, Protein A affinity chromatography, and ELISA assays.
At the conclusion of the mini-BIOMAN, participants will have a comprehensive, ready-to-insert curriculum module to utilize in their own classrooms. Curricular materials include PowerPoint slides and links to helpful resources and references, as well as hands on activities. Breakfast and lunch are provided each day of the conference, and transportation to off-site venues is included. Participation in all three days of the workshop is required.
* A limited number of $500 travel stipends are available for out-of-town participants.
** Individuals who have not previously received travel stipends for NBC2 events, and those incorporating materials & content into their programs will be given preference.
*** Registration will remain open until all participant positions are filled.
LOGIN
You need an account to do that
Please register for an account first. If you already have one, log in here.